持续性镜下血尿与IgA肾病肾脏结局的系统综述
该系统综述纳入9篇报告(8个独立队列,4776例参与者),评估持续性镜下血尿与IgA肾病肾脏结局的关联。主要分析显示持续性镜下血尿与肾脏病进展相关(HR 2.64,95%CI 2.00-3.47,I²=0%),替代分析结果一致(HR 2.26,95%CI 1.54-3.31)。结论认为持续性镜下血尿与IgA肾病肾脏病进展相关,纵向评估可能提供额外预后信息。
要点
- 持续性镜下血尿与IgA肾病肾脏病进展显著相关(HR 2.64)。
- 替代队列分析结果一致,关联不受单一研究驱动。
- 纵向评估镜下血尿可能辅助常规生物标志物进行风险分层。
核心结论
- 持续性镜下血尿与IgA肾病患者的肾脏病进展相关。
- 纵向评估镜下血尿可能提供常规生物标志物之外的额外预后信息。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Web of Science至2026年7月28日。
- 纳入9篇报告,代表8个独立队列,共4776例参与者。
- 采用随机效应模型合并分类时间-事件估计值(风险比),优先使用校正估计值,异质性用I²统计量和限制性最大似然估计评估。
主要发现
- 包含Yu等队列的分析中,6项研究(n=3,031;423个事件)显示持续性镜下血尿与肾脏病进展相关(HR 2.64;95%CI 2.00-3.47;I²=0%)。
- Hartung-Knapp调整后结果一致(HR 2.64;95%CI 2.25-3.09)。
- 以Tang等更新队列替代Yu等队列的替代分析证实关联(n=3,469;703个事件;HR 2.26;95%CI 1.54-3.31;I²=26.5%),Hartung-Knapp估计相似(HR 2.26;95%CI 1.53-3.33)。
- 留一法分析显示 findings 并非由任何单一研究驱动。
- 连续性血尿指标普遍提示更高肾脏风险,但因效应尺度不兼容未进行合并。
临床怎么用
- 在IgA肾病风险分层中,可考虑纵向评估持续性镜下血尿。
- 持续性镜下血尿可能提示需加强监测或干预,但需前瞻性研究明确其作用。
局限性
- 连续性血尿指标因定义和尺度异质性未进行合并。
- 纳入研究为观察性设计,可能存在残余混杂。
- 持续性镜下血尿在风险分层和治疗监测中的角色尚需前瞻性研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IgA nephropathy (IgAN) is a common glomerulonephritis, but the prognostic relevance of persistent microscopic hematuria remains uncertain. Persistent hematuria may reflect glomerular inflammation and complement proteinuria and estimated glomerular filtration rate (eGFR) in longitudinal assessment. We evaluated its association with kidney outcomes. METHODS: MEDLINE, Embase, and Web of Science were searched through July 28, 2026, for studies evaluating longitudinal or persistent microscopic hematuria in IgAN. Categorical time-to-event estimates were pooled as hazard ratios (HRs) using random-effects models. Adjusted estimates were prioritized, and heterogeneity was assessed using the I 2 statistic and restricted maximum likelihood estimation. Continuous estimates were summarized because of heterogeneous definitions and scales. RESULTS: A total of 9 reports representing 8 independent cohorts and 4776 participants were eligible. In the analysis including the Yu et al. cohort, 6 studies (n = 3,031; 423 events) showed that persistent microhematuria was associated with kidney disease progression (HR: 2.64; 95% confidence interval [CI]: 2.00-3.47; I 2 = 0%). Results remained consistent after Hartung-Knapp adjustment (HR: 2.64; 95% CI: 2.25-3.09). An alternative analysis replacing Yu et al. with the updated Tang et al. cohort confirmed this association (n = 3,469; 703 events; HR: 2.26; 95% CI: 1.54-3.31; I 2 = 26.5%), with similar Hartung-Knapp estimates (HR: 2.26; 95% CI: 1.53-3.33). Leave-one-out analyses showed that the findings were not driven by any single study. Continuous hematuria measures generally indicated higher kidney risk but were not pooled because of incompatible effect scales. CONCLUSIONS: Persistent microscopic hematuria is associated with kidney disease progression in IgAN. Longitudinal assessment may provide additional prognostic information alongside conventional biomarkers. Prospective studies should define its role in risk stratification and treatment monitoring.
引用
- Berti GM, Vetrano D, Tringali E, et al. Systematic Review of Persistent Microscopic Hematuria and Kidney Outcomes in IgAN. Kidney Int Rep. 2026. PMID: 42835070. doi:10.1016/j.ekir.2026.107038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。